【摘要】 目的研究瑞巴派特灌肠联合低分子肝素在溃疡性结肠炎(ulcerative colitis,UC)中的应用价值。方法纳入2013年9月至2016年9月本院收治的80例UC患者为研究对象,随机分为两组,每组均40例。对照组行常规治疗,观察组在此基础上行瑞巴派特灌肠联合低分子肝素治疗。比较两组治疗效果、预后转归及不良反应,记录两组患者血液流变学和血清炎性因子水平变化情况。结果观察组总有效率95.00%,显著高于对照组的75.00%(P<0.05)。治疗1 w和治疗结束隔日,观察组高切变率全血粘度、低切变率全血粘度及D-二聚体均显著低于对照组和治疗前(均P<0.05);观察组IL-8、TNF-α及CRP均显著低于治疗前和对照组(均P<0.05)。两组不良反应总发生率差异无统计学意义(P>0.05)。结论瑞巴派特灌肠联合低分子肝素用于UC患者,治疗效果显著,安全性良好,有助于提高治愈率。更多还原

【Abstract】 Objective To study the clinical effect of Rebamipide enema combined with low molecular weight heparin in ulcerative colitis. Methods 80 patients with UC were recruited in our hospital and were randomly assigned to two group, with 40 eases in each group. The treatment group received Rebamipide enema combined with low molecular weight heparin, and the control group received routine treatment. The therapeutic effect, prognosis and adverse reactions were compared between the two groups. The changes of hemorheology and serum inflammatory factors were measured. Results The total effective rate in the treatment group was 95.00%,which was significantly higher than that in the control group(75.00%)(P < 0.05). One day and 1 week after treatment, the high and low shear rate of whole blood viscosity, D-Dimer, the IL-8, TNF-α and CRP levels in the treatment group were significantly lower than those before treatment and those in the control group(P < 0.05). There was no significant difference in overall rate of adverse events between the two groups(P > 0.05). Conclusion Rebamipide enema combined with low molecular weight heparin for UC patients has significant treatment effect and safety, with improved cure rate.更多还原